

AK Medical (1789 HK)

High-margin customized and revision products to drive long-term growth

AK Medical reported 2021 revenue/ attribute net profit of RMB761.4mn/ RMB92.6mn, down 26.5%/ 70.5% YoY, primarily affected by the sharp retail price cuts of hip/knee joint products covered by the national VBP. The price cut has led to channel destocking during 2H21, while the actual surgery volume remained stable in 2021. The Company's income from hip and knee implants was RMB636.9mn (-31.9% YoY) in 2021. Excluding the impact of RMB103.8mn sales provision of joint implants affected by the VBP, the actual sales of hip and knee implants decreased by 20.8% YoY in 2021. During national VBP, AK Medical's all four product lines won a total of 20% of the procurement volume, ranking the first among all brands, indicating around 100,000 units procurement volume per year. In addition, winning the VBP tenders will also enable AK Medical to expand its sales channels to the majority of tired hospitals in China.

- High-margin customized and revision products to drive the growth.** AK Medical has a comprehensive product portfolio with high-margin products safe from VBP risks. Revision products accounted for 15.1% of the total revenue in 2021 while customized products contributed 2.6% during the same period. AK Medical has leading positioning in revision products in China and may benefit from the strong demand growth in revision surgeries in coming years. Revision products generally are sold at much higher prices than primary joint implants, and thus has higher margins. Furthermore, leveraging on its advanced technology in 3D printing, AK Medical is expanding its Innovative Customized Orthopedic Solution (ICOS) services, including preoperative planning, bone model printing, customized vetting guide, 3D-printed customized implants, etc. The Company already has two 3D-printing customized products obtained NMPA Class-III certificates and 28 customized products filings with cooperating hospitals. We expect the Company's ICOS income to grow rapidly from RMB23.3mn in 2021 to c. RMB100mn in 2023E.
- Increasing investment in innovation.** In 2021, AK Medical's R&D expenses was up 7.7% YoY, indicating 14.8% R&D expense ratio. The Company will continue to invest in R&D of innovative technology and products. The Company aims to obtain approvals from the NMPA for its Hip VTS Navi System and Portable Robotic System in 2022E and approvals for orthopedic surgical robot systems in 2023E. The Company is also actively developing Ortho-biological materials, with three products to be approved in 2022E.
- Maintain BUY.** We expect the Company to resume solid growth from FY22E thanks to the strong growth in high-margin products. We expect AK Medical's FY22E/23E revenue to grow 37%/ 31% YoY, and attributable net profit to grow 75%/ 47% YoY from the low base in 2021. We revised our TP to HK\$7.69 (WACC: 10.7%, Terminal growth 3.0%).

Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	1,035	761	1,045	1,367	1,746
YoY growth (%)	11.7	-26.5	37.2	30.9	27.7
Net income (RMB mn)	314	93	162	238	338
EPS (RMB)	0.28	0.08	0.15	0.21	0.30
YoY growth (%)	11.0	-70.8	74.5	46.7	42.0
Consensus EPS (RMB)	N/A	N/A	0.20	0.25	0.29
P/E (x)	12.2	41.9	24.0	16.4	11.5
P/B (x)	1.9	1.9	1.8	1.7	1.5
Yield (%)	1.0	0.6	1.0	1.5	2.2
ROE (%)	15.4	4.6	7.5	10.2	13.1
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price **HK\$7.69**
(Previous TP **HK\$11.45**)
Up/Downside **+80.94%**
Current Price **HK\$4.25**

China Healthcare Sector

Jill Wu, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	4,742
Avg 3 mths t/o (HK\$ mn)	24.38
52w High/Low (HK\$)	16.28/ 3.50
Total Issued Shares (mn)	1,116

Source: Bloomberg

Shareholding Structure

Management	57.38%
OrbiMed	7.50%
Hillhouse	7.26%
Free float	27.86%

Source: HKEx

Share Performance

	Absolute	Relative
1-mth	-21.9%	-16.9%
3-mth	-33.0%	-27.3%
6-mth	-60.8%	-55.7%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: KPMG

Related Reports

- Big winner in National VBP – 15 Sep 2021
- Results of volume-based procurement to come out in mid-September – 26 Aug 2021
- Channel destocking may continue – 27 Jul 2021

Figure 1: CMBIGM earnings revisions

(RMB mn)	New			Old			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	1,045	1,367	1,746	1,069	1,377	N/A	-2.2%	-0.7%	N/A
Gross profit	627	834	1,082	695	923	N/A	-9.7%	-9.6%	N/A
Operating profit	183	272	389	296	411	N/A	-38.2%	-34.0%	N/A
Net profit	162	238	338	253	350	N/A	-36.0%	-32.0%	N/A
EPS (RMB)	0.15	0.21	0.30	0.23	0.31	N/A	-36.1%	-32.1%	N/A
Gross margin	60.00%	61.00%	62.00%	65.00%	67.00%	N/A	-5.00 ppt	-6.00 ppt	N/A
Operating margin	17.48%	19.87%	22.29%	27.67%	29.86%	N/A	-10.19 ppt	-10.00 ppt	N/A
Net Margin	15.51%	17.38%	19.33%	23.69%	25.38%	N/A	-8.19 ppt	-8.00 ppt	N/A

Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

(RMB mn)	New			Consensus			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	1,045	1,367	1,746	1,110	1,365	1,776	-5.9%	0.2%	-1.7%
Gross profit	627	834	1,082	701	865	N/A	-10.6%	-3.6%	N/A
Operating profit	183	272	389	233	332	364	-21.4%	-18.1%	6.9%
Net profit	162	238	338	223	285	318	-27.3%	-16.6%	6.1%
EPS (RMB)	0.15	0.21	0.30	0.20	0.25	0.29	-27.38%	-15.80%	4.32%
Gross margin	60.00%	61.00%	62.00%	63.20%	63.38%	N/A	-3.20 ppt	-2.38 ppt	N/A
Operating margin	17.48%	19.87%	22.29%	20.95%	24.29%	20.50%	-3.47 ppt	-4.42 ppt	+1.79 ppt
Net Margin	15.51%	17.38%	19.33%	20.09%	20.88%	17.91%	-4.58 ppt	-3.50 ppt	+1.43 ppt

Source: Company data, CMBIGM estimates

Valuation

Figure 3: DCF valuation

DCF Valuation (in RMB mn)	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
EBIT	183	272	389	459	537	623	717	817	923
Less: tax	(29)	(42)	(60)	(73)	(86)	(100)	(115)	(131)	(148)
Depreciation and amortization	74	74	74	88	102	119	137	156	176
CAPEX	(80)	(80)	(80)	(94)	(110)	(128)	(147)	(168)	(190)
Change in working capital	282	(11)	(26)	(31)	(36)	(42)	(48)	(54)	(62)
FCF	431	213	298	348	407	473	543	620	700
Terminal value									9,369
Subtotal	431	213	298	348	407	473	543	620	10,069

PV of enterprise (RMB mn)	6,092
Net debt (RMB mn)	(944)
Equity value (RMB mn)	7,036
Equity value (HK\$ mn)	8,580
Number of shares	1,116
Price per share (HK\$)	7.69

Terminal growth rate	3.0%
WACC	10.70%
Cost of equity	13.5%
Cost of debt	5.0%
Equity Beta	1
Risk free rate	3.98%
Market Risk premium	9.50%
Target Debt to Asset ratio	30.0%
Effective Corporate Tax Rate	16.0%

Source: Company data, CMBIGM estimates

Financial Summary

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	1,035	761	1,045	1,367	1,746	EBIT	369	99	183	272	389
Knee replacement implants	258	167	218	287	373	D&A	61	74	74	74	74
Hip replacement implants	677	469	657	841	1,052	Change in working capital	(186)	11	282	(11)	(26)
3D-printed products	6	23	58	105	157	Income tax paid	(45)	(16)	(29)	(42)	(60)
Third party orthopedic products	69	79	83	92	101	Others	7	(0)	-	-	-
Other	25	22	28	42	63	Net cash from operating	205	169	511	293	378
Cost of sales	(321)	(262)	(418)	(533)	(663)	Capex	(351)	(106)	(80)	(80)	(80)
Gross profit	715	499	627	834	1,082	Other	(6)	9	8	8	8
Other income and gains	5	6	5	5	5	Net cash from investing	(356)	(97)	(72)	(72)	(72)
Distribution expenses	(154)	(187)	(240)	(301)	(367)	Net proceeds equity financing	701	-	-	-	-
Administrative expenses	(83)	(105)	(104)	(130)	(157)	Dividend paid	(75)	(23)	(41)	(59)	(84)
R&D expenses	(105)	(113)	(104)	(137)	(175)	Others	(14)	-	-	-	-
Operating profit	369	99	183	272	389	Net cash from financing	612	(23)	(41)	(59)	(84)
Net finance income / (expenses)	8	9	8	8	8	Net change in cash	461	49	398	161	221
Exceptional	-	-	-	-	-	Cash at the beginning year	277	713	476	874	1,035
Pre-tax profit	377	109	191	280	397	Exchange difference	(24)	-	-	-	-
Profits tax	(63)	(16)	(29)	(42)	(60)	Cash at the end	713	476	874	1,035	1,256
Minority interest	-	-	-	-	-						
Net profit	314	93	162	238	338						

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Non-current assets	624	671	677	683	688	Sales mix (%)					
PP&E	364	382	401	419	437	Knee replacement implants	24.9	22.0	20.8	21.0	21.4
Intangible assets	76	80	67	55	42	Hip replacement implants	65.4	61.7	62.9	61.5	60.2
Deferred tax assets	51	76	76	76	76	3D-printed products	0.6	3.1	5.6	7.7	9.0
Other non-current asset	-	-	-	-	-	Third party orthopedic products	6.7	10.4	8.0	6.7	5.8
						Other	2.5	2.9	2.7	3.1	3.6
Current assets	1,903	1,934	2,363	2,712	3,167	Total	100.0	100.0	100.0	100.0	100.0
Inventories	361	423	412	467	545	Profit & loss ratios (%)					
Trade receivables	552	530	572	704	860	Gross margin	69.0	65.6	60.0	61.0	62.0
Prepayments & other receivables	34	28	28	28	28	Net margin	30.3	12.2	15.5	17.4	19.3
Available-for-sale financial assets	188	366	366	366	366	Effective tax rate	16.6	14.7	357.4	15.0	15.0
Cash and cash equivalents	713	476	874	1,035	1,256	Balance sheet ratios					
Current liabilities	418	489	802	979	1,187	Current ratio (x)	4.6	4.0	2.9	2.8	2.7
Payables	318	260	573	749	957	Trade receivables turnover days	126	183	150	150	150
Current tax	42	52	52	52	52	Trade payables turnover days	143	204	200	200	200
Contract liabilities	46	167	167	167	167	Inventory turnover days	320	498	360	320	300
Provision	-	-	-	-	-	Net debt to total equity ratio (%)	Net cash				
Non-current liabilities	66	84	84	84	84	Returns (%)					
Deferred revenue	12	12	12	12	12	ROE	15.4	4.6	7.5	10.2	13.1
Deferred tax liabilities	39	41	41	41	41	ROA	12.4	3.6	5.3	7.0	8.8
Total net assets	2,043	2,032	2,153	2,331	2,584	Per share data					
Minority interest	-	-	-	-	-	EPS (RMB)	0.28	0.08	0.15	0.21	0.30
Shareholders' equity	2,043	2,032	2,153	2,331	2,584	DPS (RMB)	0.03	0.02	0.04	0.05	0.08
						BVPS (RMB)	1.9	1.8	1.9	2.1	2.3

Source: Company data, CMBIGM estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.